Skip to main content
Show — Main navigation
Hide — Main navigation
Home
About
The Chair
Inquiry Team
Expert Groups
Inquiry Intermediaries
Core Participants
Legal Representatives
Financial Reports
Approach
Terms of reference
List of Issues
Statements of approach
Inquiry Principles
News
News
Newsletter Archive
Reports
The Inquiry Report
Additional Compensation Report
First Interim Report
Second Interim Report
Compensation Framework Study
Evidence
Evidence
Hearings Archive
Compensation
Support
NHS Psychological Support
Confidential Psychological Support
Support Groups
Infected Blood Support Schemes
Treatment and aftercare
Medical Evidence
Expenses Guidance
Contact us
Search
Accessibility Tool
Zoom in
Zoom out
Reset
Contrast
Accessibility tool
Listen
Get in touch
Quick Exit
Subscribe to Search results
Search
Sort your search results
Relevance
Title
Changed
In the minutes of the 163rd regional transfusion directors' meeting, the chairman was recorded as saying that 90% of the plasma production for Factor 8 concentrate had already been achieved.
Published on:
30 August, 2024
In response to a parliamentary question, Roland Moyle stated that the production of Factor 8 estimated in 1975 was exceeded by July 1977 and production had risen substantially since then.
Published on:
30 August, 2024
In a note to Dr Maycock, Dr Ellis expressed that expansion to producing 25 million international units of Factor 8 per year would cause a serious overcrowding of facilities, unless some additional building work was done.
Published on:
30 August, 2024
In her evidence Dr Walford agreed that it was or should have been known to all those involved with BPL in the second half of the 1970s that the demand for blood products was rising, that it was or should have been obvious that BPL was outdated and too small, and that significant investment was required in order to be able to meet the rising demand, and that the Government had determined that BPL should meet standards equivalent to those expected of commercial plants.
Published on:
30 August, 2024
Dr Waiter wrote in a memo that in order to meet the anticipated demand for the principal plasma fractions, a new plant would have to be acquired. Plans for the future development of BPL had by this time been drawn up.
Published on:
30 August, 2024
Concerned with costs, the DHSS advised that there was no money available for either the stop-gap proposals or an upgrade of BPL.
Published on:
30 August, 2024
In a letter, J Brown advised Mr Williams that the Medicines Inspectorate report had highlighted the severe shortcomings of the standards at BPL and that had the laboratory not had Crown immunity activities would have been suspended immediately.
Published on:
30 August, 2024
John Harley wrote a memo that noted he had tried to dissuade the Scientific and Technical Committee from initiating planning as no decision had yet been taken to build a new fractionation plant at BPL and there was no budget for even a development plan.
Published on:
17 October, 2024
Dr Vaughan, then the Minister of State for Health, agreed to there being a short-term upgrade to BPL and further exploration of options for rebuilding within the NHS or in collaboration with industry.
Published on:
30 August, 2024
Ministers asked to see whether there might be scope for further savings in the stop-gap measures as they were concerned that there might be no justification to incur short-term costs on upgrading if BPL was to be rebuilt.
Published on:
30 August, 2024
Dr Lane sent a letter to Mr Harley of the DHSS enclosing a paper titled "Reviewed Interim Budget Submission 1980/81, Capital Forecast Expenditure".
Published on:
17 October, 2024
A meeting was held to discuss expenditure on the upgrading of BPL. It was determined that proposals would be put forward on the basis that only £500,000 was available to spend on short-term developments at BPL.
Published on:
25 October, 2024
Dr Vaughan finally approved a submission that had been put to him proposing expenditure of £1.3 million over two years.
Published on:
11 October, 2024
Peter Wormald noted in a memo that the success of the extra expenditure would depend on persuading RHAs to increase plasma supplies.
Published on:
30 August, 2024
Long-term upgrading was considered at a meeting of the Scientific and Technical Committee.
Published on:
30 August, 2024
It was reported to the Committee that officials had been instructed by ministers to investigate the possibility of collaborating with private industry. Initial discussions had taken place.
Published on:
30 August, 2024
Worries were expressed on various aspects of collaboration with private industry, including the fear it would be difficult to prevent the contamination of UK material with imported Hepatitis viruses.
Published on:
10 October, 2024
In a DHSS press release, Dr Vaughan announced there would be no commercial management of BPL as there was a modernisation programme already underway.
Published on:
17 October, 2024
Dr Dunhill, a member of the Scientific and Technical Committee, wrote to Dr Vaughan outlining his acceptance of the situation in the short term only from consideration of the need to maintain plasma fraction supply.
Published on:
30 August, 2024
A minister asked the Policy Steering Group for the development of BPL to give consideration to the use of an existing factory which could be adapted at a relatively low cost to meet requirements.
Published on:
30 August, 2024
Pagination
First page
First
Previous page
Previous
…
Page
2128
Page
2129
Page
2130
Page
2131
Current page
2132
Page
2133
Page
2134
Page
2135
Page
2136
…
Next page
Next
Last page
Last